{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "12145189", "DateCompleted": {"Year": "2003", "Month": "03", "Day": "20"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "09"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0959-6658", "JournalIssue": {"Volume": "12", "Issue": "8", "PubDate": {"Year": "2002", "Month": "Aug"}}, "Title": "Glycobiology", "ISOAbbreviation": "Glycobiology"}, "ArticleTitle": "Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides.", "Pagination": {"StartPage": "485", "EndPage": "497", "MedlinePgn": "485-97"}, "Abstract": {"AbstractText": ["Production of biochemically defined recombinant mistletoe lectin was achieved by cloning and separate expression of the single catalytically active A-chain and the B-chain with carbohydrate binding properties in Escherichia coli, yielding an active heterodimeric protein named rViscumin (Eck et al. [1999] Eur. J. Biochem., 265, 788-797). Employing solid phase binding assays, rViscumin was shown to preferentially bind to terminally alpha2-6-sialylated neolacto-series gangliosides IV(6)Neu5Ac-nLc4Cer, VI(6)Neu5Ac-nLc6Cer, and VIII(6)Neu5Ac-nLc8Cer isolated from human granulocytes. Only marginal binding of rViscumin to galactose-terminated neutral GSLs was determined, whereas reinvestigation of ricin specificity demonstrated this lectin as a galactose-binding protein. Human promyelotic HL-60 cells exhibited an IC(50) value (half maximum cytotoxicity) of 1.16 pM and human bladder carcinoma 5637 cells of 12.1 pM rViscumin; CHO-K1 cells were resistant to rViscumin treatment up to a concentration of 5.26 nM tested. Quantification of the predominant receptor ganglioside IV(6)Neu5Ac-nLc4Cer by means of a specific anti-Neu5Acalpha2-6Galbeta1-4GlcNAc-R antibody revealed 3.68 x 10(6) and 1.54 x 10(6) receptor molecules per HL-60 and 5637 cell, respectively; CHO-K1 cells were negative, lacking alpha2-6-sialylated gangliosides. The data imply a direct correlation of rViscumin cytotoxicity and the expression of receptor ganglioside. Moreover, CHO-K1 cells were rendered susceptible toward rViscumin cytotoxicity after exogenous application of human granulocyte gangliosides. Thus, (1) rViscumin has to be considered as a sialic acid-specific rather than a galactose-specific type II ribosome-inactivating protein, and (2) neolacto-series gangliosides with Neu5Acalpha2-6Galbeta1-4GlcNAc-terminus are true functional and physiologically relevant rViscumin receptors."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute for Medical Physics and Biophysics, University of M\u00fcnster, Robert-Koch-Str. 31, D-48149 M\u00fcnster, Germany. jm@uni-muenster.de"}], "Identifier": [], "LastName": "M\u00fcthing", "ForeName": "Johannes", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Burg", "ForeName": "Monika", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "M\u00f6ckel", "ForeName": "Babette", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Langer", "ForeName": "Martin", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Metelmann-Strupat", "ForeName": "Wolfgang", "Initials": "W"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Werner", "ForeName": "Andreas", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Neumann", "ForeName": "Ulrich", "Initials": "U"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Peter-Katalinic", "ForeName": "Jasna", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Eck", "ForeName": "J\u00fcrgen", "Initials": "J"}], "PublicationTypeList": ["Comparative Study", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Glycobiology", "NlmUniqueID": "9104124", "ISSNLinking": "0959-6658"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Gangliosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Glycosphingolipids"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Lectins"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Preparations"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Cell Surface"}, {"RegistryNumber": "0", "NameOfSubstance": "Recombinant Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Ribosome Inactivating Proteins, Type 2"}, {"RegistryNumber": "0", "NameOfSubstance": "Sialic Acids"}, {"RegistryNumber": "0", "NameOfSubstance": "Toxins, Biological"}, {"RegistryNumber": "0", "NameOfSubstance": "ribosome inactivating protein, Viscum"}, {"RegistryNumber": "9009-86-3", "NameOfSubstance": "Ricin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "CHO Cells"}, {"QualifierName": [], "DescriptorName": "Carbohydrate Sequence"}, {"QualifierName": [], "DescriptorName": "Cricetinae"}, {"QualifierName": ["chemistry", "isolation & purification", "metabolism", "pharmacokinetics"], "DescriptorName": "Gangliosides"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Glycosphingolipids"}, {"QualifierName": [], "DescriptorName": "HL-60 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Plant Lectins"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology"], "DescriptorName": "Plant Preparations"}, {"QualifierName": [], "DescriptorName": "Plant Proteins"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, Cell Surface"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Recombinant Proteins"}, {"QualifierName": [], "DescriptorName": "Ribosome Inactivating Proteins, Type 2"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ricin"}, {"QualifierName": ["chemistry"], "DescriptorName": "Sialic Acids"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "Substrate Specificity"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology"], "DescriptorName": "Toxins, Biological"}, {"QualifierName": [], "DescriptorName": "Tumor Cells, Cultured"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2002", "Month": "7", "Day": "30", "Hour": "10", "Minute": "0"}, {"Year": "2003", "Month": "3", "Day": "21", "Hour": "4", "Minute": "0"}, {"Year": "2002", "Month": "7", "Day": "30", "Hour": "10", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["12145189", "10.1093/glycob/cwf062"]}}], "PubmedBookArticle": []}